Literature DB >> 2553992

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

K B Tan1, M R Mattern, W K Eng, F L McCabe, R K Johnson.   

Abstract

Topoisomerase inhibitors comprise an important group of agents that is used in cancer treatment. Because the development of resistance to cancer chemotherapeutic agents represents a major limitation of cancer chemotherapy, we investigated the mechanism of resistance by murine P388 leukemia to camptothecin (topoisomerase I inhibitor) or amsacrine (topoisomerase II inhibitor). The resistant cells contained reduced levels of topoisomerase activity and messenger RNA. The topoisomerase gene of these cells was rearranged (only in one allele) and hypermethylated. These topoisomerase gene alterations probably resulted in reduced transcription and, thus, enzyme production, which was correlated with resistance to the topoisomerase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553992     DOI: 10.1093/jnci/81.22.1732

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  28 in total

1.  Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance.

Authors:  Yuanyuan Zhao; Fei Chen; Yuanming Pan; Zhipeng Li; Xiangdong Xue; Chukwunweike Ikechukwu Okeke; Yifeng Wang; Chan Li; Ling Peng; Paul C Wang; Xiaowei Ma; Xing-Jie Liang
Journal:  ACS Appl Mater Interfaces       Date:  2015-08-19       Impact factor: 9.229

2.  Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.

Authors:  Jean-François Marquis; Isabelle Hardy; Martin Olivier
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

Authors:  Salomé Paillas; Florence Boissière; Fréderic Bibeau; Amélie Denouel; Caroline Mollevi; Annick Causse; Vincent Denis; Nadia Vezzio-Vié; Laetitia Marzi; Cédric Cortijo; Imade Ait-Arsa; Nadav Askari; Philippe Pourquier; Pierre Martineau; Maguy Del Rio; Céline Gongora
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

4.  Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

Authors:  Zhiyong Liao; Robert W Robey; Josée Guirouilh-Barbat; Kenneth K W To; Orsolya Polgar; Susan E Bates; Yves Pommier
Journal:  Mol Pharmacol       Date:  2007-11-05       Impact factor: 4.436

5.  Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.

Authors:  Thorsten Simon; Alfred Längler; Urs Harnischmacher; Michael C Frühwald; Norbert Jorch; Alexander Claviez; Frank Berthold; Barbara Hero
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

6.  Methylated BNIP3 gene in colorectal cancer prognosis.

Authors:  Sayaka Shimizu; Satoru Iida; Megumi Ishiguro; Hiroyuki Uetake; Toshiaki Ishikawa; Yoko Takagi; Hirotoshi Kobayashi; Tetsuro Higuchi; Masayuki Enomoto; Kaoru Mogushi; Hiroshi Mizushima; Hiroshi Tanaka; Kenichi Sugihara
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

7.  Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.

Authors:  Sivakumar Vijayaraghavalu; Josephine Kamtai Dermawan; Venugopalan Cheriyath; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

8.  Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin.

Authors:  A Gaumann; D S Tews; T Mentzel; P K Petrow; E Mayer; M Otto; C J Kirkpatrick; J Kriegsmann
Journal:  Virchows Arch       Date:  2003-05-13       Impact factor: 4.064

Review 9.  Topoisomerase II in multiple drug resistance.

Authors:  G A Hofmann; M R Mattern
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs.

Authors:  Wanyi Tai; Ran Mo; Yue Lu; Tianyue Jiang; Zhen Gu
Journal:  Biomaterials       Date:  2014-05-27       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.